Aptamer Group PLC (APTA.L)
LSE · GBp · Healthcare · Biotechnology
£0.3156 (+0.19%) as of
Key statistics
- Market cap
- 10.95M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.3000 – 1.1500
- Beta
- 0.86
- Revenue (TTM)
- 1.54M
- Profit margin
- -120.60%
- Volume
- 2.59M
About Aptamer Group PLC
Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- York, United Kingdom
- Employees
- 34
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.